Policy / Pricing EFPIA report adds to pressures on EU drug pricing policy PharmaphorumPharma trade body EFPIA says access to new medicines is worsening across Europe, as it makes the socioeconomic case for spending more on novel drugs.Read full story pharminent June 24, 2026 (Last updated: June 24, 2026) Pharmaphorum Pharma trade body EFPIA says access to new medicines is worsening across Europe, as it makes the socioeconomic case for spending more on novel drugs. Read full story Post navigation Previous: Pfizer drug acquired in Seagen deal disappoints in lung cancer studyNext: Boehringer and Combotope partner for cancer antibodies Related Stories Policy / Pricing Mid-cap biotechs join Trump’s latest round of drug pricing deals pharminent September 1, 2026 Policy / Pricing MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones pharminent August 27, 2026 Policy / Pricing MFN affecting Swiss medicines access, says Interpharma pharminent August 13, 2026